PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
PharmaTher Holdings Ltd.’s affiliate, Sairiyo Therapeutics, has finalized the necessary clinical and regulatory groundwork to commence a Phase 1 trial in Australia for their patented version of the drug cepharanthine, aimed at treating infectious diseases and cancer. This study will take advantage of Australia’s lucrative tax incentives for drug development, with plans to expand trials to the U.S. Cepharanthine, a long-used drug in Japan, has been reformulated by Sairiyo for better oral absorption, potentially maximizing its therapeutic benefits.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.
